Literature DB >> 28581465

Severe acute GvHD following administration of ipilimumab for early relapse of AML after haploidentical stem cell transplantation.

F-X Gros1, T Cazaubiel1, E Forcade1, N Lechevalier2, T Leguay1, V Servant3, R Tabrizi1, L Clement1, P-Y Dumas1, A Bidet2, A Pigneux1, S Vigouroux1, N Milpied1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28581465     DOI： 10.1038/bmt.2017.78

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN： 0268-3369            Impact factor:   5.483


× No keyword cloud information.
  13 in total

1.  Ipilimumab for Patients with Relapse after Allogeneic Transplantation.

Authors:  Matthew S Davids; Haesook T Kim; Pavan Bachireddy; Caitlin Costello; Rebecca Liguori; Alexandra Savell; Alexander P Lukez; David Avigan; Yi-Bin Chen; Peter McSweeney; Nicole R LeBoeuf; Michael S Rooney; Michaela Bowden; Chensheng W Zhou; Scott R Granter; Jason L Hornick; Scott J Rodig; Masahiro Hirakawa; Mariano Severgnini; F Stephen Hodi; Catherine J Wu; Vincent T Ho; Corey Cutler; John Koreth; Edwin P Alyea; Joseph H Antin; Philippe Armand; Howard Streicher; Edward D Ball; Jerome Ritz; Asad Bashey; Robert J Soiffer
Journal:  N Engl J Med       Date:  2016-07-14       Impact factor: 91.245

2.  Fatal GvHD induced by PD-1 inhibitor pembrolizumab in a patient with Hodgkin's lymphoma.

Authors:  A K Singh; L F Porrata; O Aljitawi; T Lin; L Shune; S Ganguly; J P McGuirk; S Abhyankar
Journal:  Bone Marrow Transplant       Date:  2016-04-25       Impact factor: 5.483

3.  Cytotoxic T-lymphocyte-associated antigen-4.

Authors:  April K S Salama; F Stephen Hodi
Journal:  Clin Cancer Res       Date:  2011-04-05       Impact factor: 12.531

4.  Long-term outcome and prognostic factors of second allogeneic hematopoietic stem cell transplant for acute leukemia in patients with a median follow-up of ⩾10 years.

Authors:  G Andreola; M Labopin; D Beelen; P Chevallier; R Tabrizi; A Bosi; M Michallet; S Santarone; G Ehninger; E Polge; D Laszlo; C Schmid; A Nagler; M Mohty
Journal:  Bone Marrow Transplant       Date:  2015-09-21       Impact factor: 5.483

Review 5.  Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet.

Authors:  Hartmut Döhner; Elihu H Estey; Sergio Amadori; Frederick R Appelbaum; Thomas Büchner; Alan K Burnett; Hervé Dombret; Pierre Fenaux; David Grimwade; Richard A Larson; Francesco Lo-Coco; Tomoki Naoe; Dietger Niederwieser; Gert J Ossenkoppele; Miguel A Sanz; Jorge Sierra; Martin S Tallman; Bob Löwenberg; Clara D Bloomfield
Journal:  Blood       Date:  2009-10-30       Impact factor: 22.113

6.  Azacitidine and donor lymphocyte infusions as first salvage therapy for relapse of AML or MDS after allogeneic stem cell transplantation.

Authors:  T Schroeder; A Czibere; U Platzbecker; G Bug; L Uharek; T Luft; A Giagounidis; F Zohren; I Bruns; C Wolschke; K Rieger; R Fenk; U Germing; R Haas; N Kröger; G Kobbe
Journal:  Leukemia       Date:  2013-01-14       Impact factor: 11.528

7.  Prognostic factors in adult patients up to 60 years old with acute myeloid leukemia and translocations of chromosome band 11q23: individual patient data-based meta-analysis of the German Acute Myeloid Leukemia Intergroup.

Authors:  Jürgen Krauter; Katharina Wagner; Irina Schäfer; Rolf Marschalek; Claus Meyer; Gerhard Heil; Markus Schaich; Gerhard Ehninger; Dietger Niederwieser; Rainer Krahl; Thomas Büchner; Cristina Sauerland; Brigitte Schlegelberger; Konstanze Döhner; Hartmut Döhner; Richard F Schlenk; Arnold Ganser
Journal:  J Clin Oncol       Date:  2009-04-20       Impact factor: 44.544

8.  CTLA-4 expressed by chemoresistant, as well as untreated, myeloid leukaemia cells can be targeted with ligands to induce apoptosis.

Authors:  Stefania Laurent; Giulio L Palmisano; Alberto M Martelli; Tomohiro Kato; Pier Luigi Tazzari; Ivana Pierri; Marino Clavio; Beatrice Dozin; Giuseppe Balbi; Mauro Megna; Anna Morabito; Teresa Lamparelli; Andrea Bacigalupo; Marco Gobbi; Maria Pia Pistillo
Journal:  Br J Haematol       Date:  2007-02       Impact factor: 6.998

9.  CTLA4 blockade with ipilimumab to treat relapse of malignancy after allogeneic hematopoietic cell transplantation.

Authors:  Asad Bashey; Bridget Medina; Sue Corringham; Mildred Pasek; Ewa Carrier; Linda Vrooman; Israel Lowy; Scott R Solomon; Lawrence E Morris; H Kent Holland; James R Mason; Edwin P Alyea; Robert J Soiffer; Edward D Ball
Journal:  Blood       Date:  2008-10-30       Impact factor: 22.113

10.  CTLA-4 is not restricted to the lymphoid cell lineage and can function as a target molecule for apoptosis induction of leukemic cells.

Authors:  Maria Pia Pistillo; Pier Luigi Tazzari; Giulio Lelio Palmisano; Ivana Pierri; Andrea Bolognesi; Francesca Ferlito; Paolo Capanni; Letizia Polito; Marina Ratta; Stefano Pileri; Milena Piccioli; Giuseppe Basso; Laura Rissotto; Roberto Conte; Marco Gobbi; Fiorenzo Stirpe; Giovanni Battista Ferrara
Journal:  Blood       Date:  2002-08-15       Impact factor: 22.113
View more
  3 in total

Review 1.  Natural killer cell-based immunotherapy for acute myeloid leukemia.

Authors:  Jing Xu; Ting Niu
Journal:  J Hematol Oncol       Date:  2020-12-07       Impact factor: 17.388

Review 2.  Post-hematopoietic stem cell transplantation relapse: Role of checkpoint inhibitors.

Authors:  Elham Roshandel; Farzaneh Tavakoli; Sayeh Parkhideh; Sedigheh Sadat Akhlaghi; Maria Tavakoli Ardakani; Masoud Soleimani
Journal:  Health Sci Rep       Date:  2022-03-08

Review 3.  Translating recent advances in the pathogenesis of acute myeloid leukemia to the clinic.

Authors:  Jan Philipp Bewersdorf; Omar Abdel-Wahab
Journal:  Genes Dev       Date:  2022-03-01       Impact factor: 11.361
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.